key: cord-0980361-5blsvpyd
authors: Fang, Xiang; Cui, Tao; Qiu, Jianqing; Duan, Hong; Zhang, Wenli
title: Diagnostic accuracy of Augurix COVID‐19 IgG test
date: 2020-12-01
journal: Eur J Clin Invest
DOI: 10.1111/eci.13450
sha: 8ae2404741dc9e866702cea82f56d91a43841d42
doc_id: 980361
cord_uid: 5blsvpyd

With interest, we have read the article by Andrey et al. on a coronavirus disease 2019 (COVID-19) rapid test, published in the European Journal of Clinical Investigation in October 2020.1 The authors aimed to validate the diagnostic accuracy of a recently released IgG rapid diagnostic test (RDT) (Augurix; GaDia, Switzerland) for COVID-19. Overall, 46 confirmed COVID-19 patients and 45 heathy participants were enrolled in this unmatched 1:1 case-control study. With reference to the IgG recombinant immunofluorescence assay (rIFA) and CE-marked enzyme linked immunosorbent assay (ELISA), sensibility (SE), specificity (SP), negative predictive value (NPV), and positive predictive value (PPV) were calculated as the diagnostic accuracy estimates of Augurix IgG-RDT for COVID-19.

Dear Editors, With interest, we have read the article by Andrey et al 1 on a coronavirus disease 2019 (COVID-19) rapid test, published in the European Journal of Clinical Investigation in October 2020. The authors aimed to validate the diagnostic accuracy of a recently released IgG rapid diagnostic test (RDT) (Augurix; GaDia, Switzerland) for COVID-19. Overall, 46 confirmed COVID-19 patients and 45 heathy participants were enrolled in this unmatched 1:1 case-control study. With reference to the IgG recombinant immunofluorescence assay (rIFA) and CE-marked enzyme-linked immunosorbent assay (ELISA), sensibility (SE), specificity (SP), negative predictive value (NPV) and positive predictive value (PPV) were calculated as the diagnostic accuracy estimates of Augurix IgG-RDT for COVID-19. Based on these measurements, the authors concluded that this test showed a high diagnostic accuracy for COVID-19 in high prevalence areas and that this test could be a reliable diagnostic tool.

However, we wish to highlight that there exist two methodological limitations, which may affect the primary finding of the study. First, diagnostic accuracy studies should report estimations of the parameters that quantify accuracy from different perspectives. The authors reported SE, SP, NPV and PPV, which are not sufficient measures of diagnostic accuracy. Other measures, such as diagnostic odds ratio and negative-to-positive likelihood ratio, are important and should have been considered. Moreover, diagnostic added value using receiver operating characteristic curves should be documented. All these accuracy measures can be admissible, while the diagnostic added values ultimately might be clinically negligible. 2, 3 Hence, we propose that the authors report all these estimates completely so that the conclusions regarding the diagnostic accuracy of Augurix IgG-RDT for COVID-19 will be strengthened.

Second, validity (accuracy) and reliability (precision) constitute two entirely different methodological matters. 4 The authors only investigated diagnostic accuracy (validity). However, they stated in the conclusion that Augurix IgG-RDT could be a reliable diagnostic tool. Technically, in academic writing, the word reliable mostly refers to reliability or precision, which should be evaluated by different approaches, depending on the variable type: the intra-class correlation coefficient or the Bland-Altman plot for quantitative variables and the weighted kappa and the Fleiss' kappa for qualitative variables. 5 The authors have not reported on the diagnostic reliability of these tests as the primary outcome. Thus, it is inappropriate to conclude that Augurix IgG-RDT for COVID-19 could be a reliable diagnostic tool.

Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test

One-view breast tomosynthesis vs two-view mammography: a methodological issue

Cohort studies

Epidemiology beyond the basics

Clinical epidemiology: principles, methods, and applications for clinical research

The authors declare that they have no competing interests.Xiang Fang 1 Tao Cui 2,3 Jianqing Qiu 4 Hong Duan 1 Wenli Zhang 1